FIELD: chemistry.
SUBSTANCE: invention relates to immunology. Antibody and its antigen-binding fragment are provided against the epitope located in the C-terminal portion of claudin 18.2 (CLDN18.2). In addition, hybridomas producing an antibody of the invention, an antibody-containing conjugate and a diagnostic kit are described. Methods based on the use of said antibody are also examined to detect or determine the amount of CLDN18.2 in the sample, to determine the expression of CLDN18.2, to diagnose, detect or monitor the course of the cancer, and to determine whether cancer is suspected of anticancer therapy.
EFFECT: invention can find further application in the therapy and diagnosis of cancer.
25 cl, 3 dwg, 9 tbl, 9 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMBINED THERAPY WITH CLAUDINE 18.2 ANTIBODIES FOR CANCER TREATMENT | 2014 |
|
RU2699549C2 |
| COMBINED THERAPY WITH USE OF CLAUDIN 18,2 ANTIBODIES FOR CANCER TREATMENT | 2013 |
|
RU2662066C2 |
| COMBINED THERAPY USING THE ANTIBODIES TO CLAUDIN 18.2 FOR TREATMENT OF CANCER | 2013 |
|
RU2665321C2 |
| COMBINATION THERAPY USING ANTIBODIES TO CLAUDIN 18.2 FOR TREATMENT OF CANCER | 2013 |
|
RU2789478C2 |
| AGENTS FOR TREATMENT OF CLAUDIN EXPRESSING CANCER DISEASES | 2013 |
|
RU2678127C2 |
| THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER | 2014 |
|
RU2678700C2 |
| COMBINATION THERAPY USING ANTIBODIES AGAINST CLAUDIN 18.2 FOR CANCER TREATMENT | 2014 |
|
RU2792932C2 |
| ANTIBODIES USEFUL IN DIAGNOSING CANCER | 2018 |
|
RU2815883C1 |
| BISPECIFIC TRIVALENT ANTIBODIES BINDING TO CLAUDIN 6 OR CLAUDIN 18.2 AND CD3 FOR THE TREATMENT OF ONCOLOGICAL DISEASES WITH CLAUDIN EXPRESSION | 2017 |
|
RU2798988C2 |
| CANCER TREATMENT USING TARGETED ANTIBODIES IN VIVO | 2011 |
|
RU2642305C2 |
